New company OpZira formed following Alcon’s acquisition of LumiThera

(Image Credit: AdobeStock)

OpZira Inc has announced its official formation following the recently completed acquisition of LumiThera by Alcon.

As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc.¹

“OpZira was founded to bridge the gap between groundbreaking research and practical clinical tools,” said Clark Tedford, PhD, president & CEO of OpZira. “Our mission is to give eye care professionals the technology they need to detect ocular diseases earlier and monitor them more effectively.”

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.^1,2

AdaptDx Pro

The AdaptDx Pro is a wearable dark adaptometer leveraging AI to ensure a consistent patient experience. According to the company, impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the first functional signs of retinal disease. It was designed to make dark adaptation testing more accessible for eye care providers by eliminating the need for a darkroom. AdaptDx Pro has not been approved by FDA for use in detection or diagnosis of any specific ocular disease (such as AMD).²

NOVA Vision Testing System (Photos courtesy OpZira)

The NOVA Vision Testing System is a robust electrophysiology platform providing objective assessments of the entire visual and neuro-visual pathway. The Visual Evoked Potential (VEP) module is a non-invasive diagnostic test that measures the brain’s electrical response to visual stimuli and evaluates the function of the visual pathways from the eyes to the visual cortex in the brain. 

The Electroretinography (ERG) module is a diagnostic test that measures the electrical activity of the retina in response to light stimuli and assesses the function of the photoreceptors and other retinal cells by detecting electrical signals generated when the retina processes light.

The VEP module is available in the US and select international markets, while the ERG module is available outside the US.²

References:

1. OpZira, Inc. launches to advance ophthalmic diagnostics with innovative medical device portfolio. Published September 3, 2025. Accessed September 11, 2025. https://www.businesswire.com/news/home/20250903785229/en/OpZira-Inc.-Launches-to-Advance-Ophthalmic-Diagnostics-with-Innovative-Medical-Device-Portfolio?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark

2. OpZira Products. Accessed September 11, 2025. https://opzira.com/products/